T/FIF, a New Plateau Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JMarcus who wrote (832)	1/28/2002 1:34:55 PM
From: scaram(o)uche	Read Replies (3) of 2243

looks like margin for arestin third quarter was about 72%. Sales in the second quarter of marketing were slightly greater than the first, indicating that they beat "shelfing". I always consider this a decent sign. burn is ridiculously high? What would we get for our buck apart from arestin? Hype from an ATRX release, November...... There also appears to be a clear recognition that the Atridox clinical data and label are far superior to other locally-applied antimicrobial agents, which we believe provides an opportunity for CollaGenex to increase sales of Atridox significantly."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next